Next Article in Journal
Nanobioengineered Sensing Technologies Based on Cellulose Matrices for Detection of Small Molecules, Macromolecules, and Cells
Previous Article in Journal
Influence of the luxR Regulatory Gene Dosage and Expression Level on the Sensitivity of the Whole-Cell Biosensor to Acyl-Homoserine Lactone
Review

Clinical Utility of Biosensing Platforms for Confirmation of SARS-CoV-2 Infection

by 1,2,†, 3,†, 2 and 1,4,*
1
Department of Electronic Engineering, Gachon University, Seongnam-si 13120, Korea
2
School of Medicine and Pharmacy, The University of Danang, Danang 550000, Vietnam
3
TST Trading Service Technology Co., Ltd., Hochiminh City 723000, Vietnam
4
Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Biosensors 2021, 11(6), 167; https://doi.org/10.3390/bios11060167
Received: 10 April 2021 / Revised: 14 May 2021 / Accepted: 21 May 2021 / Published: 24 May 2021
(This article belongs to the Section Biosensor and Bioelectronic Devices)
Despite collaborative efforts from all countries, coronavirus disease 2019 (COVID-19) pandemic has been continuing to spread globally, forcing the world into social distancing period, making a special challenge for public healthcare system. Before vaccine widely available, the best approach to manage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is to achieve highest diagnostic accuracy by improving biosensor efficacy. For SARS-CoV-2 diagnostics, intensive attempts have been made by many scientists to ameliorate the drawback of current biosensors of SARS-CoV-2 in clinical diagnosis to offer benefits related to platform proposal, systematic analytical methods, system combination, and miniaturization. This review assesses ongoing research efforts aimed at developing integrated diagnostic tools to detect RNA viruses and their biomarkers for clinical diagnostics of SARS-CoV-2 infection and further highlights promising technology for SARS-CoV-2 specific diagnosis. The comparisons of SARS-CoV-2 biomarkers as well as their applicable biosensors in the field of clinical diagnosis were summarized to give scientists an advantage to develop superior diagnostic platforms. Furthermore, this review describes the prospects for this rapidly growing field of diagnostic research, raising further interest in analytical technology and strategic plan for future pandemics. View Full-Text
Keywords: SARS-CoV-2; COVID-19 clinical diagnostics; nucleic acid amplification; RT-PCR; RT-LAMP; optical biosensor; lateral flow assay; ELISA; electrochemical biosensor; lab-in-a-tube SARS-CoV-2; COVID-19 clinical diagnostics; nucleic acid amplification; RT-PCR; RT-LAMP; optical biosensor; lateral flow assay; ELISA; electrochemical biosensor; lab-in-a-tube
Show Figures

Figure 1

MDPI and ACS Style

Phan, L.M.T.; Tieu, M.-V.; Pham, T.-T.; Cho, S. Clinical Utility of Biosensing Platforms for Confirmation of SARS-CoV-2 Infection. Biosensors 2021, 11, 167. https://doi.org/10.3390/bios11060167

AMA Style

Phan LMT, Tieu M-V, Pham T-T, Cho S. Clinical Utility of Biosensing Platforms for Confirmation of SARS-CoV-2 Infection. Biosensors. 2021; 11(6):167. https://doi.org/10.3390/bios11060167

Chicago/Turabian Style

Phan, Le M.T., My-Van Tieu, Thi-Thu Pham, and Sungbo Cho. 2021. "Clinical Utility of Biosensing Platforms for Confirmation of SARS-CoV-2 Infection" Biosensors 11, no. 6: 167. https://doi.org/10.3390/bios11060167

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop